Journey Medical Corporation (DERM)

Market Cap	176.75M
Revenue (ttm)	56.40M
Net Income (ttm)	-8.74M
Shares Out	24.38M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	26.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	363,418
Open	7.41
Previous Close	8.54
Day's Range	6.67 - 7.50
52-Week Range	3.54 - 8.90
Beta	0.81
Analysts	Strong Buy
Price Target	12.50 (+72.4%)
Earnings Date	Aug 12, 2025

About DERM

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 12, 2021
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: DERM
• Website: https://journeymedicalcorp.com

Financial Performance

In 2024, Journey Medical's revenue was $56.13 million, a decrease of -29.11% compared to the previous year's $79.18 million. Losses were -$14.67 million, 280.8% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 72.40% from the latest price.

Price Target

$12.5

(72.40% upside)

Analyst Consensus: Strong Buy